The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00043927




Registration number
NCT00043927
Ethics application status
Date submitted
14/08/2002
Date registered
16/08/2002
Date last updated
21/08/2013

Titles & IDs
Public title
Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults
Scientific title
An Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin as Treatment for Chemotherapy-naive Patients With Extensive Disease-Small Cell Lung Cancer.
Secondary ID [1] 0 0
104864-A/389
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - topotecan/cisplatin
Treatment: Drugs - etoposide/cisplatin

Treatment: Drugs: topotecan/cisplatin


Treatment: Drugs: etoposide/cisplatin


Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival
Timepoint [1] 0 0
Secondary outcome [1] 0 0
response rates, response duration, time to progression, tolerability and patient-perceived disease status and well being for patients
Timepoint [1] 0 0

Eligibility
Key inclusion criteria
- Written informed consent (patient's written understanding of and agreement to
participate in this study).

- Patients with confirmed extensive small cell lung cancer (SCLC).

- No prior chemotherapy within 5 years of the diagnosis of SCLC.

- Presence of either measurable or non-measurable SCLC by X-ray or physical examination.

- At least 3 weeks since last major surgery (a lesser period is acceptable if decided to
be in the best interest of the patient).

- At least 24 hours since prior radiotherapy. Patients who have received radiotherapy
must have recovered from any reversible side effects, such as nausea and vomiting.

- Laboratory criteria: Patients must have adequate bone marrow reserve and adequate
kidney and liver function.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Symptoms of spreading of the disease to the brain that requires treatment with drugs
called steroids.

- Any active infection.

- Severe medical problems other than the diagnosis of SCLC, that would limit the ability
of the patient to follow study guidelines or that would expose the patient to extreme
risk.

- Ongoing or planned chemotherapy, immunotherapy, radiotherapy, or investigational
therapy for the treatment of SCLC.

- Use of an investigational drug within 30 days before the first dose of study
medication.

- Women who are pregnant or lactating.

- Patients of child-bearing potential who refuse to practice an adequate form of birth
control.

- Patients with clinical evidence of any stomach or intestinal (GI) condition.

- Patients requiring treatment with the drug cyclosporin A.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Minnesota
Country [14] 0 0
United States of America
State/province [14] 0 0
Missouri
Country [15] 0 0
United States of America
State/province [15] 0 0
Nevada
Country [16] 0 0
United States of America
State/province [16] 0 0
New Jersey
Country [17] 0 0
United States of America
State/province [17] 0 0
New Mexico
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Dakota
Country [20] 0 0
United States of America
State/province [20] 0 0
Ohio
Country [21] 0 0
United States of America
State/province [21] 0 0
Oregon
Country [22] 0 0
United States of America
State/province [22] 0 0
Pennsylvania
Country [23] 0 0
United States of America
State/province [23] 0 0
South Carolina
Country [24] 0 0
United States of America
State/province [24] 0 0
Tennessee
Country [25] 0 0
United States of America
State/province [25] 0 0
Texas
Country [26] 0 0
United States of America
State/province [26] 0 0
Virginia
Country [27] 0 0
United States of America
State/province [27] 0 0
Washington
Country [28] 0 0
United States of America
State/province [28] 0 0
West Virginia
Country [29] 0 0
United States of America
State/province [29] 0 0
Wisconsin
Country [30] 0 0
United States of America
State/province [30] 0 0
Wyoming
Country [31] 0 0
Austria
State/province [31] 0 0
Vienna
Country [32] 0 0
Belgium
State/province [32] 0 0
Charleroi
Country [33] 0 0
Belgium
State/province [33] 0 0
Edegem
Country [34] 0 0
Belgium
State/province [34] 0 0
Haine-Saint- Paul
Country [35] 0 0
Belgium
State/province [35] 0 0
Leuven
Country [36] 0 0
Belgium
State/province [36] 0 0
Liege
Country [37] 0 0
Belgium
State/province [37] 0 0
Luxembourg
Country [38] 0 0
Brazil
State/province [38] 0 0
Belo Horizonte
Country [39] 0 0
Brazil
State/province [39] 0 0
Caxias do Sul
Country [40] 0 0
Brazil
State/province [40] 0 0
Fortaleza
Country [41] 0 0
Brazil
State/province [41] 0 0
Porto Alegre
Country [42] 0 0
Brazil
State/province [42] 0 0
Rio de Janeiro
Country [43] 0 0
Brazil
State/province [43] 0 0
Salvador
Country [44] 0 0
Brazil
State/province [44] 0 0
Sao Paulo
Country [45] 0 0
Bulgaria
State/province [45] 0 0
Bourgas
Country [46] 0 0
Bulgaria
State/province [46] 0 0
Plovdiv
Country [47] 0 0
Bulgaria
State/province [47] 0 0
Sofia
Country [48] 0 0
Bulgaria
State/province [48] 0 0
Varna
Country [49] 0 0
Canada
State/province [49] 0 0
Alberta
Country [50] 0 0
Canada
State/province [50] 0 0
Manitoba
Country [51] 0 0
Canada
State/province [51] 0 0
Nova Scotia
Country [52] 0 0
Canada
State/province [52] 0 0
Ontario
Country [53] 0 0
Canada
State/province [53] 0 0
Quebec
Country [54] 0 0
Chile
State/province [54] 0 0
Santiago
Country [55] 0 0
China
State/province [55] 0 0
Beijing
Country [56] 0 0
China
State/province [56] 0 0
Shanghai
Country [57] 0 0
China
State/province [57] 0 0
Wangfujing
Country [58] 0 0
China
State/province [58] 0 0
Xian
Country [59] 0 0
Costa Rica
State/province [59] 0 0
San Jose
Country [60] 0 0
Czech Republic
State/province [60] 0 0
Hradec Kralove
Country [61] 0 0
Czech Republic
State/province [61] 0 0
Olomouc
Country [62] 0 0
Czech Republic
State/province [62] 0 0
Plzen
Country [63] 0 0
Czech Republic
State/province [63] 0 0
Praha
Country [64] 0 0
Estonia
State/province [64] 0 0
Tallinn
Country [65] 0 0
Finland
State/province [65] 0 0
Helsinki
Country [66] 0 0
Finland
State/province [66] 0 0
Kangasala
Country [67] 0 0
Finland
State/province [67] 0 0
Oulu
Country [68] 0 0
France
State/province [68] 0 0
Caen
Country [69] 0 0
France
State/province [69] 0 0
Calais Cedex
Country [70] 0 0
France
State/province [70] 0 0
Strasbourg
Country [71] 0 0
France
State/province [71] 0 0
Vesoul
Country [72] 0 0
Germany
State/province [72] 0 0
Baden-Wurttemberg
Country [73] 0 0
Germany
State/province [73] 0 0
Bayern
Country [74] 0 0
Germany
State/province [74] 0 0
Grosshansdorf
Country [75] 0 0
Honduras
State/province [75] 0 0
Tegucigalpa
Country [76] 0 0
Hungary
State/province [76] 0 0
Budapest
Country [77] 0 0
Hungary
State/province [77] 0 0
Hungary
Country [78] 0 0
Italy
State/province [78] 0 0
Liguria
Country [79] 0 0
Italy
State/province [79] 0 0
Lazio
Country [80] 0 0
Italy
State/province [80] 0 0
Roma
Country [81] 0 0
Jamaica
State/province [81] 0 0
Kingston
Country [82] 0 0
Korea, Republic of
State/province [82] 0 0
Seoul
Country [83] 0 0
Lithuania
State/province [83] 0 0
Kaunas
Country [84] 0 0
Lithuania
State/province [84] 0 0
Vilnius
Country [85] 0 0
Mexico
State/province [85] 0 0
Chihuahua
Country [86] 0 0
Mexico
State/province [86] 0 0
Guadalajara
Country [87] 0 0
Mexico
State/province [87] 0 0
Mexico City
Country [88] 0 0
Netherlands
State/province [88] 0 0
Apeldoorn
Country [89] 0 0
Netherlands
State/province [89] 0 0
Arnheim
Country [90] 0 0
Netherlands
State/province [90] 0 0
Ede
Country [91] 0 0
Netherlands
State/province [91] 0 0
Harderwijk
Country [92] 0 0
Netherlands
State/province [92] 0 0
Nieuwegein
Country [93] 0 0
New Zealand
State/province [93] 0 0
Hamilton
Country [94] 0 0
New Zealand
State/province [94] 0 0
Wellington South
Country [95] 0 0
Norway
State/province [95] 0 0
Oslo
Country [96] 0 0
Panama
State/province [96] 0 0
Panama
Country [97] 0 0
Poland
State/province [97] 0 0
Gdansk
Country [98] 0 0
Poland
State/province [98] 0 0
Kielce
Country [99] 0 0
Puerto Rico
State/province [99] 0 0
Ponce
Country [100] 0 0
Russian Federation
State/province [100] 0 0
Moscow Region
Country [101] 0 0
Russian Federation
State/province [101] 0 0
Moscow
Country [102] 0 0
Singapore
State/province [102] 0 0
Singapore
Country [103] 0 0
Slovakia
State/province [103] 0 0
Banska Bystrica
Country [104] 0 0
Slovakia
State/province [104] 0 0
Bratislava
Country [105] 0 0
Slovakia
State/province [105] 0 0
Kosice
Country [106] 0 0
Slovakia
State/province [106] 0 0
Nitra
Country [107] 0 0
South Africa
State/province [107] 0 0
Gauteng
Country [108] 0 0
Spain
State/province [108] 0 0
Lerida
Country [109] 0 0
Spain
State/province [109] 0 0
Valencia
Country [110] 0 0
Taiwan
State/province [110] 0 0
Taipei
Country [111] 0 0
United Kingdom
State/province [111] 0 0
Aberdeenshire
Country [112] 0 0
United Kingdom
State/province [112] 0 0
Nottinghamshire
Country [113] 0 0
United Kingdom
State/province [113] 0 0
Glasgow
Country [114] 0 0
United Kingdom
State/province [114] 0 0
Leeds
Country [115] 0 0
United Kingdom
State/province [115] 0 0
Leicester
Country [116] 0 0
United Kingdom
State/province [116] 0 0
Poole

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will gather and compare data about the effectiveness and safety of two different
treatments for extensive Small Cell Lung Cancer (SCLC) in patients who have not received
previous chemotherapy. One treatment will use an investigational drug in combination with an
FDA approved chemotherapy. The other treatment will use a combination of two FDA approved
chemotherapy drugs.
Trial website
https://clinicaltrials.gov/show/NCT00043927
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trial, MD
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications